NCT06937463

Brief Summary

  1. 1.Study Title:
  2. 2.Purpose of the Study:
  3. 3.Study Participants:
  4. 4.Research Methodology:
  5. 5.Safety and Efficacy Monitoring: Participants' physical function (e.g., strength, mobility) is tracked throughout the study. Patients are continuously monitored for any discomfort or adverse events during exercise sessions. Motor responses are closely observed to ensure utmost safety.
  6. 6.Study Duration:
  7. 7.Expected Results:
  8. 8.Safety Considerations:

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 16, 2024

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 20, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 22, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2025

Completed
7 months until next milestone

Results Posted

Study results publicly available

June 9, 2026

Completed
Last Updated

June 9, 2026

Status Verified

May 1, 2026

Enrollment Period

12 months

First QC Date

April 20, 2025

Results QC Date

March 19, 2026

Last Update Submit

May 13, 2026

Conditions

Keywords

ExergamingRehabilitationCritical illnessIntensive care unit-acquired weakness

Outcome Measures

Primary Outcomes (2)

  • Session Completion Rate

    Feasibility and adherence were assessed by the number of completed and discontinued exercise movements and completed sessions during the intervention period. A session was considered interrupted if terminated before completing the planned exercise set. Completed sessions rate: percentage of 10 planned sessions finished per each participants Outcomes are percentages (0-100); higher values indicate better adherence

    Baseline (at enrollment) and end of intervention (after completion of 10 sessions, up to 2 weeks)

  • Exercise Movement Completion Rate

    Feasibility and adherence were assessed by the number of completed and discontinued exercise movements during the intervention period. An exercise movement was considered discontinued if the participant stopped or was unable to complete the specific repetitions or prescribed movements within a session. Exercise movement completion rate is the percentage of prescribed movements successfully finished per each participant. Outcomes are percentages (0-100); higher values indicate better adherence.

    Baseline (at enrollment) and end of intervention (after completion of 10 sessions, up to 2 weeks)

Secondary Outcomes (4)

  • Net Exercise Time

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

  • Medical Research Council Sum Score (MRC-SS)

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

  • Functional Ambulatory Category (FAC)

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

  • ICU Mobility Scale

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

Other Outcomes (13)

  • Hand Grip Strength Test

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

  • Knee Extensor Test

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

  • EuroQol 5-Dimension 5-level(EQ-5D-5L) Index Value

    Baseline (at enrollment), Week 1 (midpoint after 1 week of intervention), and Week 2 (end of intervention after completion of 10 sessions)

  • +10 more other outcomes

Study Arms (1)

Intervetional

EXPERIMENTAL

Since study includes single arm, all participants will receive 2 weeks of exergaming rehabilitation intervetion

Device: Rehabilitation

Interventions

Unambulatory patients after critical care will receive 2 weeks of exergaming rehabilitation(Nintendo Ring Fit Adventure™) in addition to usual physical therapy in bed setting.

Intervetional

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Organ transplant recipients. Aged 18 years or older who have provided written informed consent. Patients who required critical care. Patients with restricted mobility, defined as an FAC score of 3 or less (unable to ambulate independently).

You may not qualify if:

  • Inability to follow instructions due to cognitive impairment or sedation. Hemodynamic instability precluding rehabilitation. Severe musculoskeletal limitations (e.g., unstable fractures, recent amputations) preventing exercise participation.
  • Significant sensory impairments (e.g., severe hearing or visual loss) hindering interaction with the exergaming system.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asan Medical Center

Seoul, Seoul, 05505, South Korea

Location

MeSH Terms

Conditions

Critical Illness

Interventions

Rehabilitation

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AftercareContinuity of Patient CarePatient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and Services

Limitations and Caveats

This study has several limitations. As a single-arm feasibility study without a control group, the definitive clinical efficacy of the intervention cannot be determined. Additionally, the small sample size (n=20) limits statistical power. Finally, because the study focused on a specific population (post-transplant inpatients with severe deconditioning), the findings may not be fully generalizable to other patient groups.

Results Point of Contact

Title
Won Kim, MD, PhD
Organization
Asan Medical Center

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

April 20, 2025

First Posted

April 22, 2025

Study Start

October 16, 2024

Primary Completion

September 30, 2025

Study Completion

October 31, 2025

Last Updated

June 9, 2026

Results First Posted

June 9, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

All individual patient data (IPD) used in this study will be handled in compliance with domestic privacy protection laws and relevant regulations. The privacy of study participants will be strictly safeguarded, and their personal information will not be used for purposes other than the study. When sharing data, only de-identified data that has been approved by the researchers after adequate request will be provided, and privacy protection and security will be prioritized throughout the process.

Locations